Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2022 | Mini-hyper CVD + venetoclax in patients with Ph-ALL

Jayastu Senapati • 13 Jun 2022
EHA 2022
Acute Lymphoblastic Leukemia Leukemia Mini-hyper-CVD Venetoclax

Jayastu Senapati, MBBS, MD, MD Anderson Cancer Center, Houston, TX, outlines the results of a study evaluating the efficacy and tolerability of venetoclax added to mini-hyper CVD (mHCVD) chemotherapy in patients with relapsed/refractory (R/R) B-cell or T-cell acute lymphoblastic leukemia (ALL), discussing the overall response rate (ORR) and toxicity of this combination. The study is currently exploring the markers of response to this treatment. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.

More from Jayastu Senapati

1:12
CPX-351 and gemtuzumab ozogamicin in R/R AML and MDS
Jayastu Senapati • 11 Dec 2022
1:42
ATG-based immunosuppressive therapy in elderly patients with aplastic anemia
Jayastu Senapati • 11 Dec 2022
1:17
Decitabine, venetoclax and ponatinib in patients with advanced CML and Ph+ AML
Jayastu Senapati • 11 Nov 2022
1:23
The effect of splicing factor gene mutations on the outcomes of patients with AML
Jayastu Senapati • 11 Dec 2022

Related Videos

1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
3:21
Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis • 22 Apr 2024
4:19
Blinatumomab to achieve remission and consolidation with haploSCT for pediatric ALL
Alberto Olaya-Vargas • 15 Apr 2024
3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals